You just read:

Hetero Launches Biosimilar 'Bevacizumab' for the Treatment of Metastatic Colorectal Cancer (mCRC) Under the Brand Name 'CizumabTM'

News provided by

Hetero

27 Jun, 2016, 14:59 BST